Eli Lilly and Company (NYSE: LLY) closed at a record high of $1,208.12 on Friday, June 26, 2026, after surging 7.13% in a single session. The rally added approximately $75.7 billion to the company's market capitalization, based on shares outstanding reported by The Wall Street Journal. The stock touched an intraday high of $1,215.76 before settling near the top of its range.
In pre-market trading at 4:46 a.m. EDT Monday, shares were quoted at $1,228.52, within $1.48 of the $1,230 price target set by Cantor Fitzgerald. The analyst firm reiterated its Overweight rating following the European regulatory backing for Jaypirca. Trading volume on Friday reached 7.72 million shares, approximately 2.6 times the average daily volume of 3.00 million shares seen Monday through Thursday.
The catalyst for the surge was the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issuing a positive opinion on June 25 for Jaypirca, Lilly's BTK inhibitor, as a monotherapy for adult patients with chronic lymphocytic leukemia (CLL) across all lines of therapy. The European Commission is expected to issue a final decision within one to two months. Lilly has also submitted the same data to the U.S. Food and Drug Administration, with a decision anticipated in the second half of 2026.
Paolo Ghia, a professor at Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele in Milan, commented that the trial data could “make a meaningful difference” for CLL patients. Jacob Van Naarden, president of Lilly Oncology, called Jaypirca a “meaningful new option.” The positive opinion marks a significant milestone for Lilly's oncology pipeline, which has been overshadowed by its blockbuster obesity franchise.
The magnitude of the one-day gain was striking: Lilly rose $80.43 per share, and the $75.7 billion increase in market value represents roughly 54% of Pfizer Inc.'s (NYSE: PFE) current market capitalization of $139.2 billion. For a company already valued at $1.14 trillion, the move was outsized relative to the news, especially given that the broader market was under pressure.
While Lilly rallied, the S&P 500 edged down 0.05% on Friday and lost 2.05% for the week. The Nasdaq Composite fell 0.24% on Friday and dropped 4.7% for the week, while the PHLX Semiconductor Index tumbled 7.9%. The divergence highlights how a single regulatory approval can drive capital into a mega-cap stock even as AI-linked names weigh on the broader indices.
Looking ahead, the stock's valuation support will be tested. Cantor Fitzgerald maintained its $1,230 target, while BMO Capital kept an Outperform rating. The pre-market quote already sat within 0.1% of Cantor's target, suggesting limited upside in the near term unless additional catalysts emerge. The obesity pipeline remains a key underlying driver: Reuters reported that Lilly expects its weight-loss pill, orforglipron, to launch in Europe and Britain in the second half of 2026 or early 2027, with a goal of securing public coverage. In China, the drug could launch from late 2026 to early 2027, and first-quarter GLP-1 sales through major e-commerce platforms Alibaba and JD.com reached approximately 1.4 billion yuan ($207 million), according to Jefferies.
The New York Stock Exchange cash session had not opened at 05:01 EDT. The next full U.S. market closure is July 3 for Independence Day observed, per the NYSE's 2026 holiday schedule.
